Replies to post #11845 on RespireRx Pharmaceuticals Inc (RSPI)

[nakedmouse]

>This no news scenario to shareholders has to, in everyone's mind, create substantial doub<

Of course it does and that's the plan, silly. Any immediate news would reassure retailers and perhaps convince them to hold their position. Each day that goes by you can chalk one up for the criminals.

[neuroinv]

<< Certainly a plan was in place in fear of rejection. Why not have a conference call immediately to discuss that plan and settle the troops, also indicating that we will be discussing the unfavorable outcome of the recent CX-717 psych rejection at a future time during which the details of that decision will be revealed and our opinion of as internally interpreted. >>

Because they didnt know how complete the bad news would be; Tran was not yet on board, and would only come on board if he was going to be a participant in the planning process. And the 'internal interpretation of the FDA decision'? It will never be stated--1) if you plan to ever go back to Psychiatry, it's a bad idea to give much detail about what they said and why, and what you really think of that decision 2) Why alert the competition?

<<Furthermore, you would have to believe that documents of that nature certainly would be expedited to give the company in question an immediate opportunity to perform damage control.>>

No way. The FDA takes no interest in providing damage control for companies. Not their problem.

<<This no news scenario to shareholders has to, in everyone's mind, create substantial doubt as to the integrity and confidence of Stoll's ability to execute a plan going forward. >>

"Everyone": Don't include me in that. Given my comments above, it would have been a waste of time to have an early conference call: 'There are changes that I cannot yet disclose that I think will provide shareholders reassurance that Cortex is moving forward, and we are developing a plan that will provide the Company a way forward to developing the Ampakine platform.' I've other stuff to do rather than waste my time with boilerplate. I want to see what they come up with as a plan with Tran--that's what will determine my level of confidence. In the big scheme of things, it's only anxiety that makes us think that three or four weeks makes a difference one way or another.

Inlicensing has even less appeal now than it did earlier. I would be surprised to hear anything of that nature. The niche in the plan inlicensing was supposed to fill is now taken by CX717/RD. Which I prefer.

NeuroInvestment

[Aiming4]

I can understand the desire to have a CC right away, I'd like to see one ASAP too.

But if we believe Dr. Stoll that the FDA letter hasn't arrived yet, then it simply hasn't arrived.

And it makes 100% sense to me that Cortex should thoroughly review it before making any firm decisions. Cortex needs to understand precisely why the FDA shot down CX717, and use that knowledge for future strategic planning as it's quite likely Cortex will have factor the DPP vs DNP into Cortex's strategy. DPP vs. DNP probably also affects the type partnerships that are realistic now post-IND decision.

I would also assume that Cortex will want to review the letter with their former FDA consultants - that takes time, especially when the letter hasn't even arrived yet.

Another factor not being given consideration is that phone calls are probably being made back and forth right now between Cortex and BPs and maybe other players as well (another small biotech, finaciers, etc...) that take time to evaluate.

The IND rejection radically changed the landscape for Cortex, and while I hope and expect that as much contingency planning as was possible was done ahead of time, it's still the case that a lot of dynamic events were kicked off by the IND rejection, and Cortex has to sort through those now. That takes time, especially to do it right.

Lastly, the decision on the future course of Cortex is a critical one. Personally I want it to be a well researched and considered decision, and I'm more than happy to allow the company the extra time to be confident in their decision.